Fludarabine

small molecule

Identifier: CI-DRUG-00000249
Entity page: /drug/fludarabine ↗
Edges: 1,818

Neighbours: 20 cancers1 variants10 trials10 approvals
Drawn: 41 of 41 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Fludarabine approved for …APPROVED_FOR11 of 10
→ approved for	Chronic Lymphocytic Leukemiahematologic_malignancy	supports	FDA ORIG	Chronic Lymphocytic Leukemia	1	Regulatory	openfda	graph →
→ approved for	Health Canada · CA · 2022Marketed in Canada as FLUDARABINE PHOSPHATE INJECTION, USP (DIN 02438577) under ATC L01BB05 FLUDARABINE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.

Fludarabine predicts response to …PREDICTS_RESPONSE_TO1 of 1
← predicts response to	IKZF1 Deletiondeletion_cna	sensitivity	B	B Lymphoblastic Leukemia/Lymphoma	1	Curated	civic	graph →

Fludarabine predicts response to …PREDICTS_RESPONSE_TO1 of 1

← predicts response to

IKZF1 Deletiondeletion_cna

sensitivity

B Lymphoblastic Leukemia/Lymphoma

Curated

Fludarabine investigated for …INVESTIGATED_FOR15 of 64show all (up to 200)
→ investigated for	B Lymphoblastic Leukemia/Lymphomahematologic_malignancy	supports	B	B Lymphoblastic Leukemia/Lymphoma	1	Curated	civic	graph →
→ investigated for	Mantle Cell Lymphomahematologic_malignancy	unknown	3	Mantle Cell Lymphoma	1	Curated	chembl	graph →
→ investigated for	Non-Hodgkin Lymphomahematologic_malignancy	unknown	3	Non-Hodgkin Lymphoma	1	Curated	chembl	graph →
→ investigated for	Multiple Myelomahematologic_malignancy	unknown	3	Multiple Myeloma	1	Curated	chembl	graph →
→ investigated for	Lymphomacancer_family	unknown	3	Lymphoma	1	Curated	chembl	graph →
→ investigated for	Leukemiacancer_family	unknown	3	Leukemia	1	Curated	chembl	graph →
→ investigated for	Melanomacancer_family	unknown	3	Melanoma	1	Curated	chembl	graph →
→ investigated for	Chronic Myeloid Leukemia, BCR-ABL1 Positivemolecular_subtype	unknown	3	Chronic Myeloid Leukemia, BCR-ABL1 Positive	1	Curated	chembl	graph →
→ investigated for	Acute Lymphoblastic Leukemiahematologic_malignancy	unknown	3	Acute Lymphoblastic Leukemia	1	Curated	chembl	graph →
→ investigated for	Acute Myeloid Leukemiahematologic_malignancy	unknown	3	Acute Myeloid Leukemia	1	Curated	chembl	graph →
→ investigated for	Myelodysplastic Syndromehematologic_malignancy	unknown	3	Myelodysplastic Syndrome	1	Curated	chembl	graph →
→ investigated for	Chronic Lymphocytic Leukemiahematologic_malignancy	unknown	3	Chronic Lymphocytic Leukemia	1	Curated	chembl	graph →
→ investigated for	Follicular Lymphomahematologic_malignancy	unknown	3	Follicular Lymphoma	1	Curated	chembl	graph →
→ investigated for	Primary Myelofibrosishematologic_malignancy	unknown	2	Primary Myelofibrosis	1	Curated	chembl	graph →
→ investigated for	T-Cell Non-Hodgkin Lymphomahematologic_malignancy	unknown	2	T-Cell Non-Hodgkin Lymphoma	1	Curated	chembl	graph →

Fludarabine investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 424show all (up to 200)
→ investigated in trials for	Myelodysplastic Syndromehematologic_malignancy 270 trials (61 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Myelodysplastic Syndrome	270	Observed	clinicaltrials	graph →
→ investigated in trials for	Acute Myeloid Leukemiahematologic_malignancy 217 trials (79 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Acute Myeloid Leukemia	217	Observed	clinicaltrials	graph →
→ investigated in trials for	Leukemiacancer_family 216 trials (11 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Leukemia	216	Observed	clinicaltrials	graph →
→ investigated in trials for	Chronic Lymphocytic Leukemiahematologic_malignancy 156 trials (29 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Chronic Lymphocytic Leukemia	156	Observed	clinicaltrials	graph →
→ investigated in trials for	Lymphomacancer_family 154 trials (15 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Lymphoma	154	Observed	clinicaltrials	graph →
→ investigated in trials for	Multiple Myelomahematologic_malignancy 152 trials (26 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Multiple Myeloma	152	Observed	clinicaltrials	graph →
→ investigated in trials for	Acute Lymphoblastic Leukemiahematologic_malignancy 127 trials (55 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Acute Lymphoblastic Leukemia	127	Observed	clinicaltrials	graph →
→ investigated in trials for	Non-Hodgkin Lymphomahematologic_malignancy 112 trials (29 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Non-Hodgkin Lymphoma	112	Observed	clinicaltrials	graph →
→ investigated in trials for	Melanomacancer_family 82 trials (15 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Melanoma	82	Observed	clinicaltrials	graph →
→ investigated in trials for	Mantle Cell Lymphomahematologic_malignancy 68 trials (16 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Mantle Cell Lymphoma	68	Observed	clinicaltrials	graph →
→ investigated in trials for	Myeloproliferative Neoplasm 66 trials (15 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Myeloproliferative Neoplasm	66	Observed	clinicaltrials	graph →
→ investigated in trials for	Small Lymphocytic Lymphoma 66 trials (15 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Small Lymphocytic Lymphoma	66	Observed	clinicaltrials	graph →
→ investigated in trials for	Hematopoietic and Lymphoid Cell Neoplasm 65 trials (25 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Hematopoietic and Lymphoid Cell Neoplasm	65	Observed	clinicaltrials	graph →
→ investigated in trials for	Hodgkin Lymphoma 58 trials (16 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Hodgkin Lymphoma	58	Observed	clinicaltrials	graph →
→ investigated in trials for	Adult Acute Myeloid Leukemia 55 trials (5 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Adult Acute Myeloid Leukemia	55	Observed	clinicaltrials	graph →

Fludarabine studied in …STUDIED_INderived10 of 1,319show all (up to 200)
→ studied in	NCT02498912Phase 1 · active not recruiting Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid Tumors · 1,319 trials list this drug (392 active)	—	—	Solid Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT06865664Phase 1 · recruiting FGFR4 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory Rhabdomyosarcoma · 1,319 trials list this drug (392 active)	—	—	Rhabdomyosarcoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06904066Phase 1 · recruiting Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies · 1,319 trials list this drug (392 active)	—	—	Hematopoietic and Lymphoid Cell Neoplasm,Acute Lymphoblastic Leukemia,Myelodysplastic Syndrome+1	1	Observed	clinicaltrials	graph →
→ studied in	NCT07509034Phase 1 · recruiting Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease · 1,319 trials list this drug (392 active)	—	—	Solid Neoplasm,Extrapulmonary Neuroendocrine Carcinoma,Lung Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07524530Phase 2 · not yet recruiting Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood Cancers · 1,319 trials list this drug (392 active)	—	—	Hematopoietic and Lymphoid Cell Neoplasm,Leukemia,Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07572136Phase 1 · recruiting Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TSLPR-Overexpressing B-Cell Acute Lymphoblastic Leukemia (B-ALL) · 1,319 trials list this drug (392 active)	—	—	Acute Lymphoblastic Leukemia,B Acute Lymphoblastic Leukemia	1	Observed	clinicaltrials	graph →
→ studied in	NCT07672483Phase 1 · not yet recruiting IL-12 Genetically Engineered Myeloid Cells in Participants With Relapsed, Refractory Solid Tumors · 1,319 trials list this drug (392 active)	—	—	not mapped	1	Observed	clinicaltrials	graph →
→ studied in	NCT07770802Phase 1 · recruiting Clinical Study of HS-IT101 Injection in the Treatment of Advanced Renal Cancer · 1,319 trials list this drug (392 active)	—	—	Clear Cell Renal Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07830342Phase 1 · recruiting A Clinical Study of HS-IT101 Injection in Patients With Advanced Non-Small Cell Lung Cancer · 1,319 trials list this drug (392 active)	—	—	Lung Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03412877Phase 2 · recruiting Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer · 1,319 trials list this drug (392 active)	—	—	Endocrine Neoplasm,Malignant Breast Neoplasm,Multiple Myeloma+2	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Paths